Business Standard

Covid-19: Favipiravir triggers a price war; new brand launched at Rs 39

According to industry insiders, many more brands are lined up for launch, including one from Cipla

Favipiravir, Umifenovir, atniviral, drugs, pharma, coronavirus, covid-19, sars, cov-2
Premium

Jenburkt is making favipiravir (brand name Favivent) at a pharmaceutical plant which is compliant with USFDA (US Food and Drug Administration) in the state of Telangana.

Sohini Das Mumbai
Favipiravir, used to treat Covid-19 patients with mild to moderate symptoms, is witnessing a pricing war with more brands launching the oral antiviral tablet in the market

After Mumbai's Glenmark Pharma launched the drug here for Rs 103 per tablet in June, it revised the price recently to Rs 79 a tablet. Pune's Brinton Pharma got a nod for the tablets this week and they have chosen to price it for Rs 59 per tablet. Now another Mumbai based company Jenburkt Pharma has launched it for Rs 39 per tablet.

According to industry insiders, many more brands are lined up for launch,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 25 2020 | 5:52 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com